Company
Wyeth
419 published works
FCPA Professor
A Focus On Central Europe
By Mike Koehler
Previous posts have highlighted FCPA enforcement actions concerning conduct (in whole or in part) Greece, Georgia and Ukraine, and Poland. This post highlights FCPA enforcement actions concerning conduct (in whole…
The IPKat
The enablement paradox and the danger of definitions (Wyeth v AstraZeneca)
The Federal Circuit's decision in Wyeth v AstraZeneca (No. 2024-2325) applied the enablement test to a dose invention. The case is an interesting contrast to the other recent case to…
RF EMerge
The Evolving Law of Enablement: Federal Circuit Decisions in Wyeth and Teva Form a “Yin and Yang” Framework
By Aydin H. Harston, Anh-Thu Lam
Two Federal Circuit decisions, three months apart, analyzed enablement of similarly broad method-of-treatment claims, but reached opposite outcomes. In April, the court reversed a JMOL of invalidity and reinstated a…
Drug Injury Watch
What The Depo-Provera Meningioma Warning Added In 2025 Means For New Depo-Provera Lawsuits In 2026
By Tom Lamb
Women Who Had Depo-Provera Injections Before December 2025 Label Change Can Still Sue Responsible Pharmaceutical Drug Companies (Posted by Tom Lamb at Drug Injury Watch) In December 2025, a Depo-Provera “meningioma warning” label…
Pro Te: Solutio
From the Courtroom to Capitol Hill: State Legislative Action on Failure-to-Warn Claims
By Butler Snow
When a company brings a new product to market, who has the authority to approve the product’s label and associated warnings? In most instances involving pharmaceutical drugs or medical devices,…
Drug & Device Law
Another Weird Alabama Decision
By Bexis
Alabama has always had some rather unusual jurisprudence. In product liability, the Yellowhammer State doesn’t have negligence or strict liability, but rather a hybrid called the Alabama Extended Manufacturers Liability…
Drug & Device Law
Childhood Vaccine Case Gets TwIqballed
Since the Supreme Court decided Bruesewitz v. Wyeth LLC, 562 U.S. 223 (2011), product liability litigation over childhood vaccines is rare but not extinct. As demonstrated by today’s case --…
Drug & Device Law
Connecticut Court Strikes Failure to Warn Claims against Non-NDA Holder
It’s all too much. Mass torts, especially those involving drugs or devices, suffer from a severe case of too-muchness. Too much of what? Cases, defendants, prevaricating experts, documents taken out…
Drug & Device Law
Zitney Now a Published Decision
By Bexis
A little over a month ago, we blogged about the Pennsylvania Superior Court (the Commonwealth’s general intermediate appellate court deciding a test case, Zitney v. Wyeth LLC, 2020 WL 6129173…
Drug & Device Law
No Pennsylvania Duty To Send “Dear Healthcare Provider” Letters
By Bexis
In a significant, albeit unpublished, decision, an intermediate appellate court in Pennsylvania has ruled that there is no recognized Pennsylvania common-law “duty” for prescription medical product manufacturers to send Dear…